RT Journal Article
SR Electronic
T1 Vaccine effectiveness of Ad26.COV2.S against symptomatic COVID-19 and clinical outcomes in Brazil: a test-negative study design
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.10.15.21265006
DO 10.1101/2021.10.15.21265006
A1 Ranzani, Otavio T
A1 dos Santos Leite, Rogério
A1 Castilho, Larissa Domingues
A1 Maymone Gonçalves, Crhistinne Cavalheiro
A1 Resende, Geraldo
A1 de Melo, Rosana Leite
A1 Croda, Julio
YR 2021
UL http://medrxiv.org/content/early/2021/10/18/2021.10.15.21265006.abstract
AB We used a test-negative design to estimate the vaccine effectiveness of Ad26.COV2.S (Janssen) against symptomatic COVID-19 and clinical outcomes in Mato-Grosso do Sul, Brazil. We analyzed 11,817 RT-PCR tests. The mean age was 37 (SD=17) years, 2,308 (20%) of individuals more or equal than 50 years and almost two-thirds of the population was Brown/Pardo. Adjusted effectiveness against symptomatic COVID-19 after 28 days of the single dose was 50.9% (95% CI, 35.5-63.0). Adjusted effectiveness against clinical outcomes was 72.9% (95% CI, 35.1-91.1) for hospitalization, 92.5% (95% CI, 54.9-99.6) for ICU admission, 88.7% (95% CI, 17.9-99.5) for mechanical ventilation and 90.5% (95% CI, 31.5-99.6) for death. Despite lacking precision on some estimates, a single dose of Ad26.COV2.S vaccine continues to protect specially for severe forms of COVID-19 in the context of new variants.Competing Interest StatementDr Croda reported receiving grants from the NIH and Sanofi during the conduct of the study and personal fees from Pan American Health Organization outside the submitted work. No other disclosures were reported. Funding StatementWe are grateful to the National Immunization Program, Ministry of Health, Brazil, for the vaccine supply to cover the mass campaign in the 13 municipalities in the internal borders of Mato-Grosso do Sul. JC is supported by the Oswaldo Cruz Foundation (Edital Covid-19: resposta rapida: 48111668950485). OTR is funded by a Sara Borrell fellowship (CD19/00110) from the Instituto de Salud Carlos III. OTR acknowledges support from the Spanish Ministry of Science and Innovation through the Centro de Excelencia Severo Ochoa 2019-2023 Program and from the Generalitat de Catalunya through the CERCA Program.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Ethical Committee for Research of Federal University of Mato-Grosso do Sul (CAAE: 43289221.5.0000.0021).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDeidentified databases as well as the R codes will be deposited in the repository https://github.com/juliocroda/VebraCOVID-19 https://github.com/juliocroda/VebraCOVID-19